| The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer TE Hickey, LA Selth, KM Chia, G Laven-Law, HH Milioli, D Roden, ... Nature medicine 27 (2), 310-320, 2021 | 151 | 2021 |
| Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer N Portman, S Alexandrou, E Carson, S Wang, E Lim, CE Caldon Endocrine-related cancer 26 (1), R15-R30, 2019 | 132 | 2019 |
| MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer N Portman, HH Milioli, S Alexandrou, R Coulson, A Yong, KJ Fernandez, ... Breast Cancer Research 22, 1-17, 2020 | 42 | 2020 |
| The proliferative and apoptotic landscape of basal-like breast cancer S Alexandrou, SM George, CJ Ormandy, E Lim, SR Oakes, CE Caldon International journal of molecular sciences 20 (3), 667, 2019 | 27 | 2019 |
| Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets HH Milioli, S Alexandrou, E Lim, CE Caldon Endocrine-related cancer 27 (5), R93-R112, 2020 | 23 | 2020 |
| Cyclin E2 promotes whole genome doubling in breast cancer C Lee, KJ Fernandez, S Alexandrou, CM Sergio, N Deng, S Rogers, ... Cancers 12 (8), 2268, 2020 | 20 | 2020 |
| Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition D Aziz, N Portman, KJ Fernandez, C Lee, S Alexandrou, A Llop-Guevara, ... NPJ Breast Cancer 7 (1), 111, 2021 | 8 | 2021 |
| miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma H Holliday, J Yang, E Dodson, I Nikolic, A Kamili, M Wheatley, N Deng, ... Molecular Therapy 30 (3), 1119-1134, 2022 | 5 | 2022 |
| Abstract PD2-02: Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers A Freelander, G Laven-Law, L Eshraghi, KM Chia, M Pickering, A Yong, ... Cancer Research 82 (4_Supplement), PD2-02-PD2-02, 2022 | 3 | 2022 |
| Cyclin E1 protein is stabilized in BRCA1 mutated breast cancers leading to synergy between CDK2 and PARP inhibitors D Aziz, N Portman, KJ Fernandez, C Lee, S Alexandrou, A Llop-Guevara, ... bioRxiv, 2020.01. 29.911883, 2020 | 3 | 2020 |
| The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer J Achinger-Kawecka, C Stirzaker, N Portman, E Campbell, KM Chia, Q Du, ... Nature Structural & Molecular Biology, 1-15, 2024 | 1 | 2024 |
| Epigenetic therapy targets the 3D epigenome in endocrine-resistant breast cancer J Achinger-Kawecka, C Stirzaker, N Portman, E Campbell, K Chia, Q Du, ... | 1 | 2021 |
| Abstract P4-04-12: Therapeutic targeting of CDK4/6 inhibitor resistant breast cancer E Lim, N Portman, S Alexandrou, S Haupt, Y Haupt, E Caldon Cancer Research 78 (4_Supplement), P4-04-12-P4-04-12, 2018 | 1 | 2018 |
| Abstract P4-08-16: Selective Androgen Receptor Modulators in combination with CDK4/6 inhibitors demonstrate anti-cancer activity in preclinical treatment resistant ER+ AR+ … A Freelander, G laven-Law, L Eshraghi, N Geetha, P Somerville, ... Cancer Research 83 (5_Supplement), P4-08-16-P4-08-16, 2023 | | 2023 |
| Abstract PS18-17: Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer N Portman, H Milioli, S Alexandrou, R Coulson, A Yong, K Fernandez, ... Cancer Research 81 (4_Supplement), PS18-17-PS18-17, 2021 | | 2021 |
| Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer N Portman, H Milioli, S Alexandrou, R Coulson, A Yong, K Fernandez, ... CANCER RESEARCH 81 (4), 2021 | | 2021 |
| Elucidating the mechanisms of resistance to CDK4/6 inhibitors and endocrine therapy in ER+ breast cancer S Alexandrou UNSW Sydney, 2021 | | 2021 |
| MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer E Lim, HH Milioli, S Alexandrou, R Coulson, A Yong, KJ Fernandez, ... ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 16, 110-110, 2020 | | 2020 |
| Mechanisms underlying uncontrolled genome doubling in breast cancer CS Lee, S Rogers, K Fernandez, S Alexandrou, N Deng, CM Sergio, ... Oncology Abstracts, 2019 | | 2019 |
| Supplementary Materials: Cyclin E2 Promotes Whole Genome Doubling in Breast Cancer C Lee, K Fernandez, S Alexandrou, CM Sergio, N Deng, S Rogers, ... | | |
